Oral androgen: DHT derivative

Mesterolone (Proviron)

Mesterolone (Proviron) is an orally active androgen with a terminal half-life of 12 - 13 hours on its UK label, and it is named in the WADA 2026 list of prohibited anabolic androgenic steroids.1,2

Moderate evidenceGet the app

Level after one dose

Mesterolone (Proviron) after one dose: 50% at ~12 h, 25% at 24 h, 12.5% at 36 h.

Drawn from the half-life in the app's model, ~12 h. The model's figures

Mesterolone, also written Proviron and Pro-viron on the UK label, is an orally active androgen with a methyl group at C-1.1 Gerris and colleagues give its chemical name as 1 alpha-methyl-5-alpha-androstane-17 beta-ol-3-one.3 Saartok and colleagues call it 1 alpha-methyl-5 alpha-dihydrotestosterone (1 alpha-methyl-DHT).4 The UK label lists its indication as "Androgen deficiency or male infertility when associated with primary or secondary male hypogonadism".1 The same label states: "Androgens are not suitable for enhancing muscular development in healthy individuals or for increasing physical ability".1

A search of PubMed on 16 November 2026 for mesterolone in the title or summary text returned 153 records. The Cochrane review of androgens for idiopathic oligo/asthenospermia by Vandekerckhove and colleagues, 2000, included 11 trials involving 930 patients, covering mesterolone and testosterone undecanoate as stimulatory androgens and testosterone enanthate and testosterone undecanoate as rebound androgens, and concluded: "There is not enough evidence to evaluate the use of androgens for male subfertility".5 Section 1308.13(f) of the US Code of Federal Regulations lists mesterolone among the anabolic steroids in Schedule III, and the WADA 2026 Prohibited List names it in S1.1.6,2

The UK label states that, unlike testosterone and all its derivatives used for androgen therapy, mesterolone "is not metabolised to oestrogen".1 It also states that in "its usual therapeutic dosage in normal men, Pro-viron does not significantly depress the release of gonadotrophins from the pituitary," and that "spermatogenesis is unimpaired".1

In 23 of 40 men with oligospermia treated for 6 to 9 months, Jackaman and colleagues (Clinical Endocrinology, 1977) reported a significant fall in serum testosterone (P less than 0.01) from 17.05 to 14.7 nmol/l and a significant rise in serum LH (P less than 0.01) from 2.73 to 3.61 u/l, with no significant difference in serum FSH, and no significant difference in sperm concentration across all patients (P=0.1).7 Itil and colleagues (1984) reported that 300-450 mg daily "significantly decreased both plasma testosterone and protein bound testosterone levels" in 52 depressed men.8 In 34 patients given 50 mg a day for two months, Dugeroglu and colleagues (2014) reported that total testosterone, sex-hormone binding globulin and estradiol decreased, free testosterone showed no change and the fraction of free testosterone increased.9 In the 12 hypogonadal men assigned to 100 mg daily in Jockenhövel and colleagues' 1999 trial, there was no significant increase of serum testosterone, and 5 alpha-dihydrotestosterone increased significantly in all treatment groups compared with baseline.10 In Spitz and colleagues' 1984 study of patients with primary testicular failure, 9 were given mesterolone 150 mg daily for 6 weeks, and mesterolone produced no changes in steroids, thyroid hormones, gonadotropins nor PRL, apart from a reduction in integrated and incremental TSH secretion after TRH.24

In a 1984 binding study that used rat and rabbit skeletal muscle and rat prostate for the androgen receptor, mesterolone ranked below methenolone and testosterone in androgen receptor binding relative to methyltrienolone.4 The same study reported that it "bound most avidly to sex hormone-binding globulin (SHBG)," with a relative binding affinity about 4 times that of DHT.4 The UK label states that 98% of the drug is bound to serum proteins, 40% to albumin and 58% to SHBG.1

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~12 h
Bioavailability
3%
Typical dose
25–75 mg/day
Route
Oral
Time to peak
~1.5 h

Sources in this part

  1. 1Bayer plc, 2017

The chart uses the app's half-life of 12 hours and time to peak of 1.5 hours, with the daily interval the UK label gives.1

Level over 4 days

Interval between doses

Level, as a share of the peak after one 75 mg dose

As studied: every day1.

An illustration from a pharmacokinetic model using a half-life of 12 hours. It is not a measured level or a suggested dose.

Table 3.1Pharmacokinetics7 rows
ParameterValueNote
Half-life~12 hours (the app's figure)The UK label states that drug levels in serum decrease with a terminal half-life of 12 - 13 hours.1
Bioavailability (oral)~3% (the app's figure)The UK label gives an absolute bioavailability of about 3% of the oral dose; the app's notes also give 3 to 5%, which the label does not state.1
Time to peak~1.5 hours (the app's figure)The UK label gives maximum serum drug levels of 3.1 ± 1.1 ng/ml after 1.6 ± 0.6 hours.1
Duration of activity~24 hours (the app's figure)Section 5.2 of the UK label gives no duration of action.1
AbsorptionRapid and almost complete over 25 - 100 mg (UK label)The same section of the label states the absolute bioavailability of about 3% of the oral dose.1
Protein binding98% bound to serum proteins40% to albumin and 58% to SHBG, per the UK label.1
Metabolism and excretionMetabolic clearance rate 4.4 ± 1.6 ml·min-1·kg-1 (UK label)The label states no renal excretion of unchanged drug and no conversion into oestrogens or corticoids observed, with 77% of the metabolites excreted in urine and 13% in faeces.1
4

Human studies

Table 4.1Human studies12 rows
Study and yearDesignPeopleDose and lengthMain result
WHO Task Force, 198911Randomised, double-blind, placebo-controlled, 7 centres248 infertile couples recruited; 157 with primary idiopathic testicular failure or idiopathic low sperm motility75 or 150 mg daily or placebo, 6 monthsCumulative life table pregnancy rates among all couples 8 months after randomisation: 9 ± 3% placebo, 12 ± 4% at 75 mg, 16 ± 4% at 150 mg; ratios to placebo 1.3 (0.5-3.2) and 1.8 (0.7-4.4).
Hargreave and colleagues, Scottish Infertility Group, 198412Randomised, mesterolone versus vitamin C368 men in infertile marriages9 months; the record gives no doseNo significant difference in the wife's pregnancy rate between the groups, including in men with low normal testosterone (under 16 nmol/l) and low sperm density (under 10 million/ml).
Gerris and colleagues, 19913Double-blind, placebo-controlled52 men with idiopathic oligoasthenospermia and/or teratozoospermia150 mg/d or placebo, 12 monthsOverall pregnancy rate 26% on mesterolone and 48% on placebo, which the authors call similar; motility and the proportion of normal-morphology sperm rose significantly on mesterolone, and a similar semen improvement occurred on placebo.
Bhathena and colleagues, 198713Randomised, mesterolone or placebo40 subfertile men with idiopathic oligospermiaMore than 4 months; the record gives no doseSignificant increases in semen volume (P less than .05), mean sperm concentration and mean total sperm count per ejaculate (P less than .01); motility and morphology were not modified, and the authors report it effective for sperm concentration in mild and moderate rather than severe oligospermia.
Varma and Patel, 198814Treated group; the record describes no comparison group250 men with idiopathic oligospermia (count under 20 million/ml)100-150 mg/day, 12 months115 pregnancies (46%), of which 9 aborted and 2 were ectopic; significant improvement in sperm density, total count and motility in 75 men with moderate oligospermia (count 5 to under 20 million/ml) and in 12% of the severe group (count under 5 million/ml); no significant adverse effect on testosterone levels or liver function.
Vandekerckhove and colleagues (Cochrane review), 20005Systematic review of randomised trials11 trials, 930 patients with idiopathic oligo/asthenospermiaMesterolone or testosterone undecanoate (stimulatory); testosterone enanthate or undecanoate (rebound)Versus placebo or no treatment: pregnancy odds ratio 1.10 (95% CI 0.75 to 1.61) for stimulatory androgens and 1.60 (0.42 to 6.16) for rebound androgens; little effect on endocrine outcomes and sperm parameters with stimulatory therapy and no difference in sperm parameters with rebound therapy; headaches and exanthema reported across the androgens, without saying which.
Luisi and Franchi, 198015Randomised, double-blind, mesterolone versus testosterone undecanoate26 hypogonadal men (14 mesterolone, 12 testosterone undecanoate)The record gives no dose; effects compared at 4 weeksTestosterone undecanoate was significantly better than mesterolone at 4 weeks for libido (p less than 0.001), erections (p less than 0.01), ejaculations (p less than 0.05) and mental state (p less than 0.001).
Jockenhövel and colleagues, 199910Randomised, 4 treatment groups55 hypogonadal men, 12 assigned to mesterolone100 mg orally daily, days 0 to 189Changes from presubstitution levels on mesterolone: total cholesterol +18.8 ± 2.5%, LDL cholesterol +46.4 ± 4.1%, HDL cholesterol -34.9 ± 2.5%, triglycerides +46.4 ± 10.3%.
Schubert and colleagues, 200316Prospective, randomised53 hypogonadal men (20 primary, 33 secondary hypogonadism)Mesterolone 100 mg p.o. daily, 6 monthsIn primary hypogonadism bone mineral density changed +0.8 ± 1.6% on mesterolone against +4.8 ± 0.2% on testosterone enanthate; in secondary hypogonadism only testosterone enanthate raised it.
Itil and colleagues, 19848Double-blind, placebo-controlled52 male depressed outpatients aged 26 to 53300-450 mg daily, 6 weeksDepressive symptoms improved, and improved on placebo too, with no statistically appreciable difference between mesterolone and placebo; plasma testosterone decreased.
Vogel and colleagues, 198517Double-blind, parallel, mesterolone versus amitriptylineDepressed men; the record gives no numberThe record gives no dose or lengthThe drugs were equally effective in reducing depressive symptoms, and mesterolone produced significantly fewer adverse side effects than amitriptyline.
Dugeroglu and colleagues, 20149Cross-sectional study of treated patients; the record describes no comparison group34 patients with symptoms of aging male syndrome and/or low testosterone50 mg/day orally, 2 monthsProstate volume rose in 22 patients (64.70%) and fell in 12 (35.29%), not a significant change (p less than 0.098); Aging Male Symptoms and International Prostate Symptom scores improved (p less than 0.001); total and free PSA did not change.

Two further randomised trials in men with oligospermia reported no significant benefit from mesterolone: Wang and colleagues (Fertility and Sterility, 1983), who randomised 46 men among placebo, clomiphene, mesterolone 100 mg/day, pentoxifylline and testosterone enanthate (the mesterolone group size is not given) and found a significant rise in mean sperm concentration only on clomiphene, and Aafjes and colleagues (Andrologia, 1983) in 59 men on 75 mg/day in a crossover design.18,19 In Aafjes and colleagues' trial there were 14 pregnancies, 7 under mesterolone and 7 under placebo.19

Deeper analysis: WHO Task Force trial of mesterolone in idiopathic male infertility

The World Health Organization Task Force on the Diagnosis and Treatment of Infertility reported, in the International Journal of Andrology in 1989, a prospective randomised double-blind study of 6 months of mesterolone in seven centres.11 Couples were assessed with the standardised WHO protocol, 157 of the 248 couples were selected on strict criteria, and the 91 others were either incompletely investigated or had an additional factor associated with infertility.11 Among the 157 couples, pregnancy rates were 11 ± 5% on placebo, 12 ± 5% at 75 mg and 19 ± 6% at 150 mg.11 The record reports: "There were no significant changes semen quality during the course of the study, apart from an increase in sperm concentration 3 months after the start of treatment".11 It adds that the increase "was greatest among the placebo treated group, but did not differ significantly between treatment groups".11 The PubMed record lists no individual authors, states no funding and states no limitations beyond these results.11

Deeper analysis: Gerris and colleagues, high-dose mesterolone against placebo

Gerris and colleagues, from the Department of Obstetrics and Gynecology, Middleheim General Hospital, Antwerp, reported in Fertility and Sterility in 1991 a double-blind trial of 150 mg/d of mesterolone or placebo for 12 months in 52 men with idiopathic oligoasthenospermia and/or teratozoospermia.3 The authors wrote: "our findings cast doubt on the possible usefulness of high-dose Mesterolone treatment of idiopathic male infertility".3 The text gives Schering N.V., Brussels, Belgium, in brackets after mesterolone, and the record lists "Research Support, Non-U.S. Gov't" as a publication type; it states no funder and no author tie to the maker.3

Deeper analysis: Scottish Infertility Group, mesterolone against vitamin C

Hargreave and colleagues for the Scottish Infertility Group reported in the British Journal of Urology in 1984 a randomised trial of 9 months of mesterolone or vitamin C in 368 men.12 A separate analysis restricted to men with low normal testosterone and low sperm density, married to wives with normal tubal patency and ovulation tests, also found no difference in pregnancy rates.12 The authors concluded that "mesterolone therapy given in the absence of any defined endocrinopathy is of no benefit in promoting male fertility" and that they had "been unable to find any subgroup who will respond".12 The record names no funder and lists "Research Support, Non-U.S. Gov't" as a publication type.12

5

Doses reported in studies and on labels

The app's typical dose is 25 to 75 mg/day. For adults, the UK label lists 3 or 4 tablets of 25 mg daily initially and 2-3 tablets (50-75 mg) daily as maintenance, and the trials above report 50 to 450 mg per day.1,8,9

Table 5.1Doses reported in studies and on labels11 rows
SourceDoseFrequencyLength
UK label, adults, initial13 or 4 tablets of 25 mgDailySeveral months
UK label, adults, maintenance12-3 tablets (50-75 mg)DailyNot stated
WHO Task Force, 19891175 or 150 mgDaily6 months
Gerris and colleagues, 19913150 mgPer day (150 mg/d)12 months
Wang and colleagues, 198318100 mgPer day6 months
Aafjes and colleagues, 19831975 mgPer day6 months, then crossover
Varma and Patel, 198814100-150 mgPer day12 months
Jockenhövel and colleagues, 199910100 mgOrally dailyDays 0 to 189
Dugeroglu and colleagues, 2014950 mgPer day, orally2 months
Itil and colleagues, 19848300-450 mgDaily6 weeks
Lowe and colleagues, 197920100 mgPer day21 days, 9 healthy male volunteers

The UK label states that frequent or persistent erections may occur.1 It states that "In rare cases benign, and in even rarer cases, malignant liver tumours leading in isolated cases to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as the one contained in Pro-viron".1 It lists prostatic carcinoma and previous or existing liver tumours as contraindications, and states that there have been no reports of ill-effects from overdosage.1 It also states that, in contrast to other orally active androgens, "liver tolerance is excellent".1 Varma and Patel reported no significant adverse effect on testosterone levels or on liver function in 250 men given 100-150 mg/day for 12 months.14

Lowe and colleagues (British Journal of Clinical Pharmacology, 1979) described a patient who developed deep vein thrombosis after starting mesterolone, and gave 100 mg/day for 21 days to nine healthy male volunteers.20 Among the volunteers, "No significant change after treatment occurred in any of the blood tests performed," which included clotting times, fibrinogen, platelet count, haematocrit and whole blood viscosity.20 The authors concluded that mesterolone at a conventional dose for 3 weeks "does not produce a consistent measurable prothrombotic state".20

Two case reports are listed in PubMed under the titles "Drug-induced liver injury due to mesterolone: A case report" (Pérez Palacios and colleagues, Gastroenterología y Hepatología, 2019) and "Mania related to mesterolone in a previously mentally healthy person" (Gahr and colleagues, Journal of Clinical Psychopharmacology, 2012), and neither record carries summary text.21,22 The Cochrane review, which covers mesterolone and testosterone esters, states: "Adverse effects such as headaches and exanthema were reported", and the review summary does not say which androgen.5

The app lists liver enzymes, lipids and hematocrit as health markers for this compound. In the 1999 lipid report, the authors concluded that androgen substitution in hypogonadal men "increases TC, LDL-C, and TG and decreases HDL-C independently of the androgen type and application made and the serum androgen levels achieved".10 In the 1997 report of the same four-group design (55 men), mesterolone 100 mg/d raised hemoglobin by 5.6 ± 1.8 g/l and hematocrit by 1.8 ± 0.4%, which the authors described as no significant change, against 21.1 ± 2.6 g/l and 6.4 ± 0.9% on testosterone enanthate.23 In Varma and Patel's 250 men, "Mesterolone had no depressing effect on low or normal serum FSH and LH levels but had depressing effect on 25% if the levels were elevated".14 In Dugeroglu and colleagues' 34 patients, total and free prostate-specific antigen did not change over 2 months at 50 mg/day.9 The UK label states that regular examination of the prostate during treatment is advised in order to exclude prostatic carcinoma.1

8

Regulatory and anti-doping status

The UK label text, issued by Bayer plc under marketing authorisation number PL 00010/0562, gives 01/05/2008 as the date of first authorisation and 13/12/2017 as the date of revision.1 In the United States, 21 CFR 1308.13(f), under Schedule III, covers any substance meeting the definition of anabolic steroid in section 1300.01 and lists "mesterolone (1α-methyl-17β-hydroxy-5α-androstan-3-one)" as item (45).6 The WADA 2026 Prohibited List, in effect from 1 January 2026, names mesterolone under S1.1, anabolic androgenic steroids administered exogenously.2 The list states "Anabolic agents are prohibited," that S1 is prohibited at all times, in and out of competition, and that all prohibited substances in the class are non-Specified Substances.2 It also notes that some of these substances may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.2

9

Storage and handling

Sources in this part

  1. 1Bayer plc, 2017

The UK label gives a shelf life of 5 years and, under special precautions for storage, "None".1 Each tablet contains 25 mg mesterolone with lactose, maize starch, povidone 25 000 (E1201), methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216) and magnesium stearate (E572), in a pack of 3 blister packs of 10 tablets.1

Section 5.2 of the UK label gives no duration of action, so the app's figure of about 24 hours is not matched by a label figure.1 The label states that mesterolone does not significantly depress gonadotrophin release in normal men at its usual dosage, while the studies above report a fall in testosterone or a rise in LH in men with oligospermia, depressed men and men with symptoms of aging male syndrome, at doses and durations that differ, while Spitz and colleagues reported no change in steroids or gonadotropins in men with primary testicular failure and Jockenhövel and colleagues no significant rise in serum testosterone in hypogonadal men.1,7,8,9,24,10 The Cochrane review concluded that there is not enough evidence to evaluate androgens for male subfertility, and the studies table lists no trial with a muscle or performance outcome.5

What is the half-life of Proviron?

The UK label for Pro-viron gives a terminal half-life of 12 - 13 hours.1 The app's figure is about 12 hours.

What is Proviron?

Proviron is a brand name of mesterolone, an orally active androgen with a methyl group at C-1.1

What is the bioavailability of Proviron?

The UK label gives an absolute bioavailability of about 3% of the oral dose.1 The same section states that mesterolone is rapidly and almost completely absorbed in a wide dose range of 25 - 100 mg.1

How long does Proviron take to peak?

The UK label gives maximum serum drug levels of 3.1 ± 1.1 ng/ml after 1.6 ± 0.6 hours.1 The app's figure is about 1.5 hours.

Is Proviron banned by WADA?

Mesterolone is named in S1.1 (anabolic androgenic steroids) of the WADA 2026 Prohibited List.2 Class S1 is prohibited at all times, in and out of competition.2

Is mesterolone a Schedule III substance in the US?

21 CFR 1308.13(f) lists mesterolone among the anabolic steroids under Schedule III.6

Does Proviron convert to estrogen?

The UK label states that mesterolone "is not metabolised to oestrogen" and that no metabolic conversion into oestrogens or corticoids has been observed.1 In 34 patients given 50 mg a day for two months, in a study whose record describes no comparison group, serum estradiol decreased.9

Does Proviron improve male fertility in trials?

In the WHO Task Force double-blind trial, cumulative pregnancy rates among all couples 8 months after randomisation were 9% on placebo, 12% at 75 mg and 16% at 150 mg, with ratios to placebo of 1.3 (0.5-3.2) and 1.8 (0.7-4.4).11 Gerris and colleagues reported pregnancy rates of 26% on mesterolone and 48% on placebo, which they described as similar, and the Scottish Infertility Group found no significant difference against vitamin C.3,12 Bhathena and colleagues reported significant increases in sperm concentration and total sperm count against placebo, with motility and morphology not modified, and found it effective in mild and moderate rather than severe oligospermia.13 The Cochrane review reported a pregnancy odds ratio of 1.10 (95% CI 0.75 to 1.61) for stimulatory androgens against placebo or no treatment, and Wang and Aafjes and colleagues reported no significant benefit from mesterolone.5,18,19

What does Proviron do to cholesterol?

In 12 hypogonadal men given 100 mg orally daily from days 0 to 189, compared with levels before treatment, total cholesterol rose 18.8 ± 2.5%, LDL cholesterol rose 46.4 ± 4.1%, HDL cholesterol fell 34.9 ± 2.5% and triglycerides rose 46.4 ± 10.3%.10 The authors reported the same direction of change in the testosterone undecanoate, testosterone enanthate and testosterone pellet groups, and included only men with total cholesterol and triglycerides under 200 mg/dL before treatment.10

13

References

  1. Bayer plc. Pro-viron 25 mg tablets: summary of product characteristics (UK, PL 00010/0562). Text revised 13 December 2017. UK label (SmPC)
  2. World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
  3. Gerris J, Comhaire F, Hellemans P, Peeters K, Schoonjans F. Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility. Fertil Steril 1991. PMID 1900485
  4. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984. PMID 6539197
  5. Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000. PMID 10796496
  6. US Code of Federal Regulations. Title 21, section 1308.13, Schedule III (anabolic steroids, paragraph (f)). 21 CFR 1308.13
  7. Jackaman FR, et al. The hormone response to a synthetic androgen (mesterolone) in oligospermia. Clin Endocrinol (Oxf) 1977. PMID 872444
  8. Itil TM, Michael ST, Shapiro DM, Itil KZ. The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). Methods Find Exp Clin Pharmacol 1984. PMID 6431212
  9. Dugeroglu H, Ozturk M, Atmaca M, Seven I. Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. J Pak Med Assoc 2014. PMID 25842579
  10. Jockenhövel F, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999. PMID 10337859
  11. WHO Task Force on the Diagnosis and Treatment of Infertility. Mesterolone and idiopathic male infertility: a double-blind study. Int J Androl 1989. PMID 2680994
  12. Hargreave TB, et al. Randomised trial of mesterolone versus vitamin C for male infertility. Scottish Infertility Group. Br J Urol 1984. PMID 6398725
  13. Bhathena RK, Jassawalla MJ, Patel DN. The effects of mesterolone on sperm count in idiopathic oligospermia. Int J Fertil 1987. PMID 2887529
  14. Varma TR, Patel RH. The effect of mesterolone on sperm count, on serum follicle stimulating hormone, luteinizing hormone, plasma testosterone and outcome in idiopathic oligospermic men. Int J Gynaecol Obstet 1988. PMID 2892728
  15. Luisi M, Franchi F. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 1980. PMID 7000879
  16. Schubert M, et al. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003. PMID 12792150
  17. Vogel W, Klaiber EL, Broverman DM. A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. J Clin Psychiatry 1985. PMID 3880735
  18. Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983. PMID 6411497
  19. Aafjes JH, van der Vijver JC, Brugman FW, Schenck PE. Double-blind cross over treatment with mesterolone and placebo of subfertile oligozoospermic men value of testicular biopsy. Andrologia 1983. PMID 6364886
  20. Lowe GD, Thomson JE, Reavey MM, Forbes CD, Prentice CR. Mesterolone: thrombosis during treatment, and a study of its prothrombotic effects. Br J Clin Pharmacol 1979. PMID 760733
  21. Pérez Palacios D, et al. Drug-induced liver injury due to mesterolone: A case report. Gastroenterol Hepatol 2019. PMID 31405534
  22. Gahr M, Kölle MA, Baumgarten E, Freudenmann RW. Mania related to mesterolone in a previously mentally healthy person. J Clin Psychopharmacol 2012. PMID 22926621
  23. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997. PMID 9233903
  24. Spitz IM, Margalioth EJ, Yeger Y, Livshin Y, Zylber-Haran E, Shilo S. Effect of non aromatizable androgens on LHRH and TRH responses in primary testicular failure. Horm Metab Res 1984. PMID 6437958